Clinical potential of novel therapeutic targets in breast cancer: CDK4/6, Src, JAK/STAT, PARP, HDAC, and PI3K/AKT/mTOR pathways

References

• American Cancer SocietyBreast Cancer: Facts and Figures 2013–2014Atlanta, GAAmerican Cancer Society, Inc2013
   Google Scholar
• CurtisCShahSPChinSFThe genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroupsNature2012486740334635222522925
   PubMed Web of Science ®Google Scholar
• SørlieTPerouCMTibshiraniRGene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implicationsProc Natl Acad Sci U S A20019819108691087411553815
   PubMed Web of Science ®Google Scholar
• PratAParkerJSKarginovaOPhenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancerBreast Cancer Res2010125R6820813035
   PubMed Web of Science ®Google Scholar
• PerouCMSørlieTEisenMBMolecular portraits of human breast tumoursNature2000406679774775210963602
   PubMed Web of Science ®Google Scholar
• BertucciFFinettiPCerveraNHow basal are triple-negative breast cancers?Int J Cancer2008123123624018398844
   PubMed Web of Science ®Google Scholar
• RexerBNArteagaCLIntrinsic and acquired resistance to HER2-targeted therapies in HER2 gene-amplified breast cancer: mechanisms and clinical implicationsCrit Rev Oncog201217111622471661
   PubMedGoogle Scholar
• GiulianoMSchifpROsborneCKTrivediMVBiological mechanisms and clinical implications of endocrine resistance in breast cancerBreast201120Suppl 34249
   Web of Science ®Google Scholar
• AndersLKeNHydbringPA systematic screen for CDK4/6 substrates links FOXM1 phosphorylation to senescence suppression in cancer cellsCancer Cell201120562063422094256
   PubMed Web of Science ®Google Scholar
• HanahanDWeinbergRAHallmarks of cancer: the next generationCell2011144564667421376230
   PubMed Web of Science ®Google Scholar
• FlemingTPMatsuiTMolloyCJRobbinsKCAaronsonSAAutocrine mechanism for v-sis transformation requires cell surface localization of internally activated growth factor receptorsProc Natl Acad Sci U S A19898620806380672813378
   PubMed Web of Science ®Google Scholar
• ClarkGJDerCJAberrant function of the Ras signal transduction pathway in human breast cancerBreast Cancer Res Treat19953511331447612899
   PubMed Web of Science ®Google Scholar
• MusgroveEACaldonCEBarracloughJStoneASutherlandRLCyclin D as a therapeutic target in cancerNat Rev Cancer201111855857221734724
   PubMed Web of Science ®Google Scholar
• MalumbresMBarbacidMTo cycle or not to cycle: a critical decision in cancerNat Rev Cancer20011322223111902577
   PubMed Web of Science ®Google Scholar
• BignellGRGreenmanCDDaviesHSignatures of mutation and selection in the cancer genomeNature2010463728389389820164919
   PubMed Web of Science ®Google Scholar
• Cancer Genome Atlas NetworkComprehensive molecular portraits of human breast tumoursNature20124907418617023000897
   PubMed Web of Science ®Google Scholar
• HallMPetersGGenetic alterations of cyclins, cyclin-dependent kinases, and Cdk inhibitors in human cancerAdv Cancer Res199668671088712071
   PubMed Web of Science ®Google Scholar
• DicksonMASchwartzGKDevelopment of cell-cycle inhibitors for cancer therapyCurr Oncol2009162364319370178
   PubMed Web of Science ®Google Scholar
• BlagosklonnyMVFlavopiridol, an inhibitor of transcription: implications, problems and solutionsCell Cycle20043121537154215539947
   PubMed Web of Science ®Google Scholar
• ByrdJCShinnCWaselenkoJKFlavopiridol induces apoptosis in chronic lymphocytic leukemia cells via activation of caspase-3 without evidence of bcl-2 modulation or dependence on functional p53Blood19989210380438169808574
   PubMed Web of Science ®Google Scholar
• KitadaSZapataJMAndreeffMReedJCProtein kinase inhibitors flavopiridol and 7-hydroxy-staurosporine down-regulate antiapoptosis proteins in B-cell chronic lymphocytic leukemiaBlood200096239339710887097
   PubMed Web of Science ®Google Scholar
• ShapiroGISupkoJGPattersonAA phase II trial of the cyclin-dependent kinase inhibitor flavopiridol in patients with previously untreated stage IV non-small cell lung cancerClin Cancer Res2001761590159911410495
   PubMed Web of Science ®Google Scholar
• SchwartzGKIlsonDSaltzLPhase II study of the cyclin-dependent kinase inhibitor flavopiridol administered to patients with advanced gastric carcinomaJ Clin Oncol20011971985199211283131
   PubMed Web of Science ®Google Scholar
• AkliluMKindlerHLDonehowerRCManiSVokesEEPhase II study of flavopiridol in patients with advanced colorectal cancerAnn Oncol20031481270127312881391
   PubMed Web of Science ®Google Scholar
• LiuGGandaraDRLaraPNA Phase II trial of flavopiridol (NSC #649890) in patients with previously untreated metastatic androgen-independent prostate cancerClin Cancer Res200410392492814871968
   PubMed Web of Science ®Google Scholar
• CanaveseMSantoLRajeNCyclin dependent kinases in cancer: potential for therapeutic interventionCancer Biol Ther201213745145722361734
   PubMed Web of Science ®Google Scholar
• ToogoodPLHarveyPJRepineJTDiscovery of a potent and selective inhibitor of cyclin-dependent kinase 4/6J Med Chem20054872388240615801831
   PubMed Web of Science ®Google Scholar
• FryDWHarveyPJKellerPRSpecific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenograftsMol Cancer Ther20043111427143815542782
   PubMed Web of Science ®Google Scholar
• FinnRSDeringJConklinDPD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitroBreast Cancer Res2009115R7719874578
   PubMed Web of Science ®Google Scholar
• MillerTWBalkoJMFoxEMERα-dependent E2F transcription can mediate resistance to estrogen deprivation in human breast cancerCancer Discov20111433835122049316
   PubMed Web of Science ®Google Scholar
• ClarkeRLeonessaFWelchJNSkaarTCCellular and molecular pharmacology of antiestrogen action and resistancePharmacol Rev2001531257111171938
   PubMed Web of Science ®Google Scholar
• WattsCKBradyASarcevicBdeFazioAMusgroveEASutherlandRLAntiestrogen inhibition of cell cycle progression in breast cancer cells in associated with inhibition of cyclin-dependent kinase activity and decreased retinoblastoma protein phosphorylationMol Endocrinol1995912180418138614416
   PubMed Web of Science ®Google Scholar
• WattsCKSweeneyKJWarltersAMusgroveEASutherlandRLAntiestrogen regulation of cell cycle progression and cyclin D1 gene expression in MCF-7 human breast cancer cellsBreast Cancer Res Treat1994311951057981461
   PubMed Web of Science ®Google Scholar
• CarrollJSPrallOWMusgroveEASutherlandRLA pure estrogen antagonist inhibits cyclin E-Cdk2 activity in MCF-7 breast cancer cells and induces accumulation of p130-E2F4 complexes characteristic of quiescenceJ Biol Chem200027549382213822910991938
   PubMed Web of Science ®Google Scholar
• WilckenNRPrallOWMusgroveEASutherlandRLInducible overexpression of cyclin D1 in breast cancer cells reverses the growth-inhibitory effects of antiestrogensClin Cancer Res1997368498549815758
   PubMed Web of Science ®Google Scholar
• RudasMLehnertMHuynhAAustrian Breast and Colorectal Cancer Study GroupCyclin D1 expression in breast cancer patients receiving adjuvant tamoxifen-based therapyClin Cancer Res20081461767177418347178
   PubMed Web of Science ®Google Scholar
• BoscoEEWangYXuHThe retinoblastoma tumor suppressor modifies the therapeutic response of breast cancerJ Clin Invest2007117121822817160137
   PubMed Web of Science ®Google Scholar
• ThangavelCDeanJLErtelATherapeutically activating RB: reestablishing cell cycle control in endocrine therapy-resistant breast cancerEndocr Relat Cancer201118333334521367843
   PubMed Web of Science ®Google Scholar
• KimSLooAChopraRAbstract PR02: LEE011: an orally bioavailable, selective small molecule inhibitor of CDK4/6 – reactivating Rb in cancerMol Cancer Ther201312PR02
   Google Scholar
• SchwartzGKLoRussoPMDicksonMAPhase I study of PD 0332991, a cyclin-dependent kinase inhibitor, administered in 3-week cycles (Schedule 2/1)Br J Cancer2011104121862186821610706
   PubMed Web of Science ®Google Scholar
• FlahertyKTLorussoPMDemicheleAPhase I, dose-escalation trial of the oral cyclin-dependent kinase 4/6 inhibitor PD 0332991, administered using a 21-day schedule in patients with advanced cancerClin Cancer Res201218256857622090362
   PubMed Web of Science ®Google Scholar
• FinnRSCrownJPBoerKResults of a randomized phase 2 study of PD 0332991, a cyclin-dependent kinase (CDK) 4/6 inhibitor, in combination with letrozole vs letrozole alone for first-line treatment of ER+/HER2− advanced breast cancer(BC)2012 Cancer Res201272Suppl 24S1S6
   Google Scholar
• InfanteJRPetronellaWGerecitanoJA phase I study of the single-agent CDK4/6 inhibitor LEE011 in pts with advanced solid tumors and lymphomasJ Clin Oncol2014325s Suppl Abstract 2528
   Google Scholar
• ShapiroGLeeSTolcherAWA first-in-human phase I study of the CDK4/6 inhibitor, LY2835219, for patients with advanced cancerJ Clin Oncol201331Suppl Abstract 2500
   Google Scholar
• McClendonAKDeanJLRivadeneiraDBCDK4/6 inhibition antagonizes the cytotoxic response to anthracycline therapyCell Cycle201211142747275522751436
   PubMed Web of Science ®Google Scholar
• DeanJLMcClendonAKKnudsenESModification of the DNA damage response by therapeutic CDK4/6 inhibitionJ Biol Chem201228734290752908722733811
   PubMed Web of Science ®Google Scholar
• RobertsPJBisiJEStrumJCMultiple roles of cyclin-dependent kinase 4/6 inhibitors in cancer therapyJ Natl Cancer Inst2012104647648722302033
   PubMed Web of Science ®Google Scholar
• VivancoISawyersCLThe phosphatidylinositol 3-Kinase AKT pathway in human cancerNat Rev Cancer20022748950112094235
   PubMed Web of Science ®Google Scholar
• KatsoROkkenhaugKAhmadiKWhiteSTimmsJWaterfieldMDCellular function of phosphoinositide 3-kinases: implications for development, homeostasis, and cancerAnnu Rev Cell Dev Biol20011761567511687500
   PubMed Web of Science ®Google Scholar
• OsakiMOshimuraMItoHPI3K-Akt pathway: its functions and alterations in human cancerApoptosis20049666767615505410
   PubMed Web of Science ®Google Scholar
• MillerTWRexerBNGarrettJTArteagaCLMutations in the phosphatidylinositol 3-kinase pathway: role in tumor progression and therapeutic implications in breast cancerBreast Cancer Res201113622422114931
   PubMed Web of Science ®Google Scholar
• BurrisHA3rdOvercoming acquired resistance to anticancer therapy: focus on the PI3K/AKT/mTOR pathwayCancer Chemother Pharmacol201371482984223377372
   PubMed Web of Science ®Google Scholar
• MillerTWBalkoJMArteagaCLPhosphatidylinositol 3-kinase and antiestrogen resistance in breast cancerJ Clin Oncol201129334452446122010023
   PubMed Web of Science ®Google Scholar
• RazisEBobosMKotoulaVEvaluation of the association of PIK3CA mutations and PTEN loss with efficacy of trastuzumab therapy in metastatic breast cancerBreast Cancer Res Treat2011128244745621594665
   PubMed Web of Science ®Google Scholar
• ShomanNKlassenSMcFaddenABickisMGTorlakovicEChibbarRReduced PTEN expression predicts relapse in patients with breast carcinoma treated by tamoxifenMod Pathol200518225025915475931
   PubMed Web of Science ®Google Scholar
• SaalLHJohanssonPHolmKPoor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activityProc Natl Acad Sci U S A2007104187564756917452630
   PubMed Web of Science ®Google Scholar
• Pérez-TenorioGAlkhoriLOlssonBPIK3CA mutations and PTEN loss correlate with similar prognostic factors and are not mutually exclusive in breast cancerClin Cancer Res200713123577358417575221
   PubMed Web of Science ®Google Scholar
• Gonzalez-AnguloAmFerrer-LozanoJStemke-HaleKPI3K pathway mutations and PTEN levels in primary and metastatic breast cancerMol Cancer Ther20111061093110121490305
   PubMed Web of Science ®Google Scholar
• BendellJCRodonJBurrisHAPhase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumorsJ Clin Oncol201230328229022162589
   PubMed Web of Science ®Google Scholar
• DoiTAndoYBandoHPhase I dose-escalation study of BKM120, an oral pan-class I PI3K inhibitor, in Japanese patients with advanced solid tumorsMol Cancer Ther20111011 Supplement 1 Abstract B159
   Google Scholar
• RodonJBendellJCAbdulRARSafety profile and clinical activity of single-agent BKM120, a pan-class I PIK inhibitor, for the treatment of patients with metastatic breast carcinomaCancer Res20117124 Suppl 3 Abstract P3-16-01
   Google Scholar
• Gonzalez-AnguloAMJuricDArgilésGSafety, pharmacokinetics, and preliminary activity of the α-specific PI3K inhibitor BYL719: results from the first-in-human studyJ Clin Oncol201331Suppl Abstract 2531
   PubMedGoogle Scholar
• MillerTWHennessyBTGonzález-AnguloAMHyperactivation of phosphatidylinositol-3 kinase promotes escape from hormone dependence in estrogen receptor-positive human breast cancerJ Clin Invest201012072406241320530877
   PubMed Web of Science ®Google Scholar
• O’BrienCWallinJJSampathDPredictive biomarkers of sensitivity to the phosphatidylinositol 3′ kinase inhibitor GDC-0941 in breast cancer preclinical modelsClin Cancer Res201016143670368320453058
   PubMed Web of Science ®Google Scholar
• SheQBChandarlapatySYeQBreast tumor cells with PI3K mutation or HER2 amplification are selectively addicted to Akt signalingPLoS One200838e306518725974
   PubMed Web of Science ®Google Scholar
• IhleNTLemosRJrWipfPMutations in the phosphatidylinositol-3-kinase pathway predict for antitumor activity of the inhibitor PX-866 whereas oncogenic Ras is a dominant predictor for resistanceCancer Res200969114315019117997
   PubMed Web of Science ®Google Scholar
• WallinJJEdgarKAGuanJGDC-0980 is a novel class I PI3K/mTOR kinase inhibitor with robust activity in cancer models driven by the PI3K pathwayMol Cancer Ther201110122426243621998291
   PubMed Web of Science ®Google Scholar
• MayerIABalkoJMKubaMGSU2C phase Ib study of pan-PI3K inhibitor BKM120 plus aromatase inhibitor letrozole in ER+/HER2− metastatic breast cancer (MBC)Cancer Res20117124 Suppl 3 Abstract PD09-05
   Google Scholar
• JankuFWhelerJJWestinSNPI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutationsJ Clin Oncol201230877778222271473
   PubMed Web of Science ®Google Scholar
• MaassNHarbeckNMundhenkeCGerman Breast GroupEverolimus as treatment for breast cancer patients with bone metastases only: results of the phase II RADAR studyJ Cancer Res Clin Oncol2013139122047205624072232
   PubMed Web of Science ®Google Scholar
• CavazzoniABonelliMAFumarolaCOvercoming acquired resistance to letrozole by targeting the PI3K/AKT/mTOR pathway in breast cancer cell clonesCancer Lett20123231778722484466
   PubMed Web of Science ®Google Scholar
• GhayadSECohenPAInhibitors of the PI3K/Akt/mTOR pathway: new hope for breast cancer patientsRecent Pat Anticancer Drug Discov201051295719751211
   PubMed Web of Science ®Google Scholar
• GhayadSEBiecheIVendrellJAmTOR inhibition reverses acquired endocrine therapy resistance of breast cancer cells at the cell proliferation and gene-expression levelsCancer Sci200899101992200319016759
   PubMed Web of Science ®Google Scholar
• VilquinPVilledieuMGrisardEMolecular characterization of anastrozole resistance in breast cancer: pivotal role of the Akt/mTOR pathway in the emergence of de novo or acquired resistance and importance of combining the allosteric Akt inhibitor MK-2206 with an aromatase inhibitorInt J Cancer201313371589160223553037
   PubMed Web of Science ®Google Scholar
• BachelotTBourgierCCropetCRandomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO studyJ Clin Oncol201230222718272422565002
   PubMed Web of Science ®Google Scholar
• YardleyDANoguchiSPritchardKIEverolimus plus exemestane in postmenopausal patients with HR(+) breast cancer: BOLERO-2 final progression-free survival analysisAdv Ther2013301087088424158787
   PubMed Web of Science ®Google Scholar
• HortobagyiGNPiccart-GebhartMJRugoHSCorrelation of molecular alterations with efficacy of everolimus in hormone receptor-positive, HER2-negative advanced breast cancer: results from BOLERO-2J Clin Oncol201331Suppl Abstract LBA509
   Google Scholar
• MillerTWForbesJTShahCInhibition of mammalian target of rapamycin is required for optimal antitumor effect of HER2 inhibitors against HER2-overexpressing cancer cellsClin Cancer Res200915237266727619934303
   PubMed Web of Science ®Google Scholar
• O’ReillyKERojoFSheQBmTOR inhibition induces upstream receptor tyrosine kinase signaling and activates AktCancer Res20066631500150816452206
   PubMed Web of Science ®Google Scholar
• CarracedoAMaLTeruya-FeldsteinJInhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancerJ Clin Invest200811893065307418725988
   PubMed Web of Science ®Google Scholar
• MayerIAAbramsonVGBalkoJMSU2C phase Ib study of pan-PI3K inhibitor BKM120 with letrozole in ER+/HER2− metastatic breast cancer (MBC)J Clin Oncol201230Suppl Abstract 510
   Google Scholar
• PerezEADueckACMcCulloughAEImpact of PTEN protein expression on benefit from adjuvant trastuzumab in early-stage human epidermal growth factor receptor 2-positive breast cancer in the North Central Cancer Treatment Group N9831 trialJ Clin Oncol201331172115212223650412
   PubMed Web of Science ®Google Scholar
• BernsKHorlingsHMHennessyBTA functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancerCancer Cell200712439540217936563
   PubMed Web of Science ®Google Scholar
• O’BrienNABrowneBCChowLActivated phosphoinositide 3-kinase/AKT signaling confers resistance to trastuzumab but not lapatinibMol Cancer Ther2010961489150220501798
   PubMed Web of Science ®Google Scholar
• WangLZhangQZhangJPI3K pathway activation results in low efficacy of both trastuzumab and lapatinibBMC Cancer20111124821676217
   PubMed Web of Science ®Google Scholar
• EstevaFJGuoHZhangSPTEN, PIK3CA, p-AKT, and p-p70S6K status: association with trastuzumab response and survival in patients with HER2-positive metastatic breast cancerAm J Pathol201017741647165620813970
   PubMed Web of Science ®Google Scholar
• O’BrienNAMcDonaldKTongLPI3K/mTOR inhibition overcomes in vitro and in vivo trastuzumab resistance independent of feedback activation of pAKTCancer Res20127224 Suppl 3 Abstract P4-08-01
   Google Scholar
• SauraCBendellJJerusalemGPhase Ib study of buparlisib plus trastuzumab in patients with HER2-positive advanced or metastatic breast cancer that has progressed on trastuzumab-based therapyClin Cancer Res20142071935194524470511
   PubMed Web of Science ®Google Scholar
• MorrowPKWulfGMEnsorJPhase I/II study of trastuzumab in combination with everolimus (RAD001) in patients with HER2-overexpressing metastatic breast cancer who progressed on trastuzumab-based therapyJ Clin Oncol201129233126313221730275
   PubMed Web of Science ®Google Scholar
• WestKACastilloSSDennisPAActivation of the PI3K/Akt pathway and chemotherapeutic resistanceDrug Resist Updat20025623424812531180
   PubMed Web of Science ®Google Scholar
• MassarwehSOsborneCKCreightonCJTamoxifen resistance in breast tumors is driven by growth factor receptor signaling with repression of classic estrogen receptor genomic functionCancer Res200868382683318245484
   PubMed Web of Science ®Google Scholar
• LuYZiXZhaoYMascarenhasDPollakMInsulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin)J Natl Cancer Inst200193241852185711752009
   PubMed Web of Science ®Google Scholar
• VadgamaJVWuYDattaGKhanHChillarRPlasma insulin-like growth factor-I and serum IGF-binding protein 3 can be associated with the progression of breast cancer, and predict the risk of recurrence and the probability of survival in African-American and Hispanic womenOncology199957433034010575321
   PubMed Web of Science ®Google Scholar
• CreightonCJCasaALazardZInsulin-like growth factor-I activates gene transcription programs strongly associated with poor breast cancer prognosisJ Clin Oncol200826254078408518757322
   PubMed Web of Science ®Google Scholar
• BonneterreJPeyratJPBeuscartRDemailleAPrognostic significance of insulin-like growth factor 1 receptors in human breast cancerCancer Res19905021693169352170011
   PubMed Web of Science ®Google Scholar
• FoxEMMillerTWBalkoJMA kinome-wide screen identifies the insulin/IGF-I receptor pathway as a mechanism of escape from hormone dependence in breast cancerCancer Res201171216773678421908557
   PubMed Web of Science ®Google Scholar
• QuekRWangQMorganJACombination mTOR and IGF-1R inhibition: phase I trial of everolimus and figitumumab in patients with advanced sarcomas and other solid tumorsClin Cancer Res201117487187921177764
   PubMed Web of Science ®Google Scholar
• CaoAZPinzon-OrtizMChenYTargeting PIK3CA mutant breast cancer with the combination of PIK3CA-specific inhibitor, BYL719, and IGF1-R antibody, ganitumabJ Clin Oncol201331Suppl Abstract e13525
   Google Scholar
• FaganDHYeeDCrosstalk between IGF1R and estrogen receptor signaling in breast cancerJ Mammary Gland Biol Neoplasia200813442342919003523
   PubMed Web of Science ®Google Scholar
• CohenBDBakerDASoderstromCCombination therapy enhances the inhibition of tumor growth with the fully human anti-type 1 insulin-like growth factor receptor monoclonal antibody CP-751,871Clin Cancer Res20051152063207315756033
   PubMed Web of Science ®Google Scholar
• RobertsonJFFerreroJMBourgeoisHGanitumab with either exemestane or fulvestrant for postmenopausal women with advanced, hormone-receptor-positive breast cancer: a randomised, controlled, double-blind, phase 2 trialLancet Oncol201314322823523414585
   PubMed Web of Science ®Google Scholar
• DunnSEHardmanRAKariFWBarrettJCInsulin-like growth factor 1 (IGF-1) alters drug sensitivity of HBL100 human breast cancer cells by inhibition of apoptosis induced by diverse anticancer drugsCancer Res19975713268726939205078
   PubMed Web of Science ®Google Scholar
• GoochJLVan Den BergCLYeeDInsulin-like growth factor (IGF)-I rescues breast cancer cells from chemotherapy-induced cell death – proliferative and anti-apoptotic effectsBreast Cancer Res Treat199956111010517338
   PubMed Web of Science ®Google Scholar
• HaluskaPShawHBatzelGNPhase I dose escalation study of the anti-IGF-1R monoclonal antibody CP-751,871 in patients with refractory solid tumorsJ Clin Oncol200725Suppl 18 Abstract 3586
   Web of Science ®Google Scholar
• KarpDDPaz-AresLGNovelloSPhase II study of the anti-insulin-like growth factor type 1 receptor antibody CP-751,871 in combination with paclitaxel and carboplatin in previously untreated, locally advanced, or metastatic non-small-cell lung cancerJ Clin Oncol200927152516252219380445
   PubMed Web of Science ®Google Scholar
• NahtaRYuanLXZhangBKobayashiREstevaFJInsulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cellsCancer Res20056523111181112816322262
   PubMed Web of Science ®Google Scholar
• FriedbichlerKHofmannMHKroezMPharmacodynamic and antineoplastic activity of BI 836845, a fully human IGF ligand-neutralizing antibody, and mechanistic rationale for combination with rapamycinMol Cancer Ther201413239940924296829
   PubMed Web of Science ®Google Scholar
• ChenYCSosnoskiDMMastroAMBreast cancer metastasis to the bone: mechanisms of bone lossBreast Cancer Res201012621521176175
   PubMed Web of Science ®Google Scholar
• HershmanDLMcMahonDJCrewKDZoledronic acid prevents bone loss in premenopausal women undergoing adjuvant chemotherapy for early-stage breast cancerJ Clin Oncol200826294739474518711172
   PubMed Web of Science ®Google Scholar
• GnantMMlineritschBLuschin-EbengreuthGAustrian Breast and Colorectal Cancer Study Group (ABCSG)Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudyLancet Oncol20089984084918718815
   PubMed Web of Science ®Google Scholar
• ShapiroCLHalabiSHarsVZoledronic acid preserves bone mineral density in premenopausal women who develop ovarian failure due to adjuvant chemotherapy: final results from CALGB trial 79809Eur J Cancer201147568368921324674
   PubMed Web of Science ®Google Scholar
• GreenJRBisphosphonates: preclinical reviewOncologist20049Suppl 431315459425
   PubMed Web of Science ®Google Scholar
• WinterMCHolenIColemanREExploring the anti-tumour activity of bisphosphonates in early breast cancerCancer Treat Rev200834545347518423992
   PubMed Web of Science ®Google Scholar
• DaubinéFLe GallCGasserJGreenJClézardinPAntitumor effects of clinical dosing regimens of bisphosphonates in experimental breast cancer bone metastasisJ Natl Cancer Inst200799432233017312309
   PubMedGoogle Scholar
• OttewellPDLefleyDVCrossSSEvansCAColemanREHolenISustained inhibition of tumor growth and prolonged survival following sequential administration of doxorubicin and zoledronic acid in a breast cancer modelInt J Cancer2010126252253219621384
   PubMed Web of Science ®Google Scholar
• HiragaTWilliamsPJUedaATamuraDYonedaTZoledronic acid inhibits visceral metastases in the 4T1/luc mouse breast cancer modelClin Cancer Res200410134559456715240548
   PubMed Web of Science ®Google Scholar
• GnantMZoledronic acid in the treatment of early-stage breast cancer: is there a final verdict?Curr Oncol Rep2012141354322113793
   PubMed Web of Science ®Google Scholar
• DentRTrudeauMPritchardKITriple-negative breast cancer: clinical features and patterns of recurrenceClin Cancer Res20071315 Pt 14429443417671126
   PubMed Web of Science ®Google Scholar
• KenneckeHYerushalmiRWoodsRMetastatic behavior of breast cancer subtypesJ Clin Oncol201028203271327720498394
   PubMed Web of Science ®Google Scholar
• RoosWPKainaBDNA damage-induced cell death by apoptosisTrends Mol Med200612944045016899408
   PubMed Web of Science ®Google Scholar
• McCabeNTurnerNCLordCJDeficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibitionCancer Res200666168109811516912188
   PubMed Web of Science ®Google Scholar
• BryantHESchultzNThomasHDSpecific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymeraseNature2005434703591391715829966
   PubMed Web of Science ®Google Scholar
• FarmerHMcCabeNLordCJTargeting the DNA repair defect in BRCA mutant cells as a therapeutic strategyNature2005434703591792115829967
   PubMed Web of Science ®Google Scholar
• MuraiJHuangSYDasBBTrapping of PARP1 and PARP2 by clinical PARP inhibitorsCancer Res201272215588559923118055
   PubMed Web of Science ®Google Scholar
• MuraiJHuangSYRenaudAStereospecific PARP trapping by BMN 673 and comparison with olaparib and rucaparibMol Cancer Ther201413243344324356813
   PubMed Web of Science ®Google Scholar
• TuttARobsonMGarberJEOral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trialLancet2010376973723524420609467
   PubMed Web of Science ®Google Scholar
• TurnerNTuttAAshworthAHallmarks of ‘BRCAness’ in sporadic cancersNat Rev Cancer200441081481915510162
   PubMed Web of Science ®Google Scholar
• DentRALindemanGJClemonsMPhase I trial of the oral PARP inhibitor olaparib in combination with paclitaxel for first- or second-line treatment of patients with metastatic triple-negative breast cancerBreast Cancer Res2013155R8824063698
   PubMed Web of Science ®Google Scholar
• KristeleitRSShapiroGLoRussoPA phase I dose-escalation and PK study of continuous oral rucaparib in patients with advanced solid tumorsJ Clin Oncol201331Suppl Abstract 2585
   Google Scholar
• IsakoffSJOvermoyerBTungNMA phase II trial expansion cohort of the PARP inhibitor veliparib (ABT888) and temozolomide in BRCA1/2 associated metastatic breast cancerCancer Res20117124 Suppl 3P3-16-05
   Web of Science ®Google Scholar
• FanJYinWJLuJSER alpha negative breast cancer cells restore response to endocrine therapy by combination treatment with both HDAC inhibitor and DNMT inhibitorJ Cancer Res Clin Oncol2008134888389018264725
   PubMed Web of Science ®Google Scholar
• JangERLimSJLeeESThe histone deacetylase inhibitor trichostatin A sensitizes estrogen receptor alpha-negative breast cancer cells to tamoxifenOncogene20042391724173614676837
   PubMed Web of Science ®Google Scholar
• ThomasSThurnKTBiçakuEMarchionDCMünsterPNAddition of a histone deacetylase inhibitor redirects tamoxifen-treated breast cancer cells into apoptosis, which is opposed by the induction of autophagyBreast Cancer Res Treat2011130243744721298336
   PubMed Web of Science ®Google Scholar
• YardleyDAIsmail-KhanRRMelicharBRandomized phase II, double-blind, placebo-controlled study of exemestane with or without entinostat in postmenopausal women with locally recurrent or metastatic estrogen receptor-positive breast cancer progressing on treatment with a nonsteroidal aromatase inhibitorJ Clin Oncol201331172128213523650416
   PubMed Web of Science ®Google Scholar
• MunsterPNThurnKTThomasSA phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancerBr J Cancer2011104121828183521559012
   PubMed Web of Science ®Google Scholar
• ContePCamponeMPronzatoPPhase I trial of panobinostat (LBH589) in combination with trastuzumab in pretreated HER2-positive metastatic breast cancer (mBC): preliminary safety and tolerability resultsJ Clin Oncol20092715s Suppl Abstract 1081
   Google Scholar
• FrameMCSrc in cancer: deregulation and consequences for cell behaviorBiochim Biophys Acta20021602211413012020799
   PubMed Web of Science ®Google Scholar
• ZhangXHWangQGeraldWLatent bone metastasis in breast cancer tied to Src-dependent survival signalsCancer Cell2009161677819573813
   PubMed Web of Science ®Google Scholar
• ElsbergerBTanBAMitchellTJIs expression or activation of Src kinase associated with cancer-specific survival in ER-, PR- and HER2-negative breast cancer patients?Am J Pathol200917541389139719762712
   PubMed Web of Science ®Google Scholar
• ElsbergerBTanBAMallonEABruntonVGEdwardsJIs there an association with phosphorylation and dephosphorylation of Src kinase at tyrosine 530 and breast cancer patient disease-specific survivalBr J Cancer2010103121831183421063412
   PubMed Web of Science ®Google Scholar
• MorganLGeeJPumfordSElevated Src kinase activity attenuates Tamoxifen response in vitro and is associated with poor prognosis clinicallyCancer Biol Ther20098161550155819830888
   PubMed Web of Science ®Google Scholar
• HeroldCIChadaramVPetersonBLPhase II trial of dasatinib in patients with metastatic breast cancer using real-time pharmacodynamic tissue biomarkers of Src inhibition to escalate dosingClin Cancer Res201117186061607021810917
   PubMed Web of Science ®Google Scholar
• FinnRSBengalaCIbrahimNDasatinib as a single agent in triple-negative breast cancer: results of an open-label phase 2 studyClin Cancer Res201117216905691322028489
   PubMed Web of Science ®Google Scholar
• FedelePCalvaniNMarinoATargeted agents to reverse resistance to endocrine therapy in metastatic breast cancer: where are we now and where are we going?Crit Rev Oncol Hematol201284224325122494933
   PubMed Web of Science ®Google Scholar
• FornierMNMorrisPGAbbruzziAA phase I study of dasatinib and weekly paclitaxel for metastatic breast cancerAnn Oncol201122122575258121406471
   PubMed Web of Science ®Google Scholar
• SomloGAtzoriFStraussLCDasatinib plus capecitabine for advanced breast cancer: safety and efficacy in phase I study CA180004Clin Cancer Res20131971884189323403636
   PubMed Web of Science ®Google Scholar
• PaulDVukeljaSJHolmesFALetrozole plus dasatinib improves progression-free survival (PFS) in hormone receptor-positive, HER2-negative postmenopausal metastatic breast cancer (MBC) patients receiving first-line aromatase inhibitor (AI) therapyCancer Res201373 Abstract S3-07
   Web of Science ®Google Scholar
• Bristol-Myers SquibbSafety and efficacy of exemestane plus dasatinib versus placebo for advanced ER+ breast cancer Available from: http://clinicaltrials.gov/show/NCT00767520. NLM identifier: NCT00767520Accessed March 14, 2014
   Google Scholar
• ParganasEWangDStravopodisDJak2 is essential for signaling through a variety of cytokine receptorsCell19989333853959590173
   PubMed Web of Science ®Google Scholar
• LevineRLPardananiATefferiAGillilandDGRole of JAK2 in the pathogenesis and therapy of myeloproliferative disordersNat Rev Cancer20077967368317721432
   PubMed Web of Science ®Google Scholar
• LevineRLWadleighMCoolsJActivating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosisCancer Cell20057438739715837627
   PubMed Web of Science ®Google Scholar
• SansonePBrombergJTargeting the interleukin-6/Jak/stat pathway in human malignanciesJ Clin Oncol20123091005101422355058
   PubMed Web of Science ®Google Scholar
• MarottaLLAlmendroVMarusykAThe JAK2/STAT3 signaling pathway is required for growth of CD44+CD24− stem cell-like breast cancer cells in human tumorsJ Clin Invest201112172723273521633165
   PubMed Web of Science ®Google Scholar
• BritschgiAAndraosRBrinkhausHJAK2/STAT5 inhibition circumvents resistance to PI3K/mTOR blockade: a rationale for cotargeting these pathways in metastatic breast cancerCancer Cell201222679681123238015
   PubMed Web of Science ®Google Scholar
• CeramiEGaoJDogrusozUThe cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics dataCancer Discov20122540140422588877
   PubMed Web of Science ®Google Scholar
• GaoJAksoyBADogrusozUIntegrative analysis of complex cancer genomics and clinical profiles using the cBioPortalSci Signal20136269pl123550210
   PubMed Web of Science ®Google Scholar